Drug metabolism genotypes and their association with adverse drug reactions in selected populations: A pilot study of methodology

Pharmacoepidemiology and Drug Safety

Volumn 9, Issue 5, 2000, Pages 393-400

  Clark, David ^a   Morgan, Althea ^a   Hananeia, Lynne ^b   Coulter, David ^b   Olds, Robin ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adverse drug reactions; CYP2C19; CYP2D6; Drug metabolism; Genetic polymorphism; Genotype frequencies; Pharmacogenetics; Pilot study; Population study

Indexed keywords

CYTOCHROME P450 2C19; DEBRISOQUINE 4 HYDROXYLASE; FLUOXETINE; MOCLOBEMIDE; OMEPRAZOLE;

ABDOMINAL PAIN; ALLELE; ARTHRALGIA; ARTICLE; ATAXIA; BLOOD DONOR; COMPLEX PARTIAL SEIZURE; CONFUSION; CONTROLLED STUDY; DEPERSONALIZATION; DIARRHEA; DISORIENTATION; DRUG METABOLISM; DRUG MONITORING; DYSTONIA; DYSURIA; GENE LOCUS; GENOTYPE; HEART PALPITATION; HUMAN; HYPONATREMIA; INSOMNIA; MAJOR CLINICAL STUDY; METHODOLOGY; MUSCLE HYPERTONIA; NAUSEA; PILOT STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; TREMOR; VOMITING; XEROSTOMIA;

EID: 0033760330     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1557(200009/10)9:5<393::AID-PDS519>3.0.CO;2-L     Document Type: Article

References (19)

1. Polymorphic human cytochrome P450 enzymes: An opportunity for individualised drug treatment
2. Molecular mechanisms of genetic polymorphisms of drug metabolism
3. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype
4. Genetically determined variability in acetylation and oxidation: Therapeutic implications
5. Pharmacogenetics of antidepressants: Clinical aspects
6. Nomenclature for human CYP2D6 alleles
7. The New Zealand intensive medicines monitoring programme
8. Adverse effects from metoprolol are not generally associated with oxidation status
9. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population
10. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
11. Detection of the poor metaboliser-associated CYP2D6(D) gene deletion allele by long-PCR technology
12. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
13. Association between CYP2C19 genotype and proguanil oxidative polymorphism
14. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequency and phenotypic consequences
15. Impaired oxidation of debrisoquine in patients with peripheral neuropathy
16. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
17. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
18. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine
19. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy